CRISPR Therapeutics AG
CRSP
$57.75
-$2.25-3.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -97.58% | 47.67% | 72.53% | 71.63% | -82.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.58% | 47.67% | 72.53% | 71.63% | -82.26% |
| Cost of Revenue | 67.04% | 24.33% | -13.04% | 5.57% | -28.65% |
| Gross Profit | -193.49% | -24.18% | 13.37% | -5.30% | -153.99% |
| SG&A Expenses | 1.52% | -2.80% | -2.90% | 7.48% | 9.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.20% | 20.06% | -11.74% | 5.81% | -23.81% |
| Operating Income | -139.62% | -19.91% | 12.02% | -5.57% | -192.82% |
| Income Before Tax | -255.08% | -24.40% | -65.65% | -16.42% | -140.87% |
| Income Tax Expenses | -12.29% | -29.34% | 0.39% | 53.18% | 200.43% |
| Earnings from Continuing Operations | -250.07% | -23.85% | -64.98% | -16.64% | -141.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -250.07% | -23.85% | -64.98% | -16.64% | -141.76% |
| EBIT | -139.62% | -19.91% | 12.02% | -5.57% | -192.82% |
| EBITDA | -149.56% | -21.10% | 12.29% | -5.84% | -180.21% |
| EPS Basic | -214.02% | -15.62% | -60.91% | -11.02% | -138.94% |
| Normalized Basic EPS | -218.57% | -16.13% | 13.48% | -10.81% | -138.10% |
| EPS Diluted | -214.04% | -15.84% | -61.07% | -10.66% | -139.88% |
| Normalized Diluted EPS | -218.57% | -16.13% | 13.48% | -10.81% | -138.89% |
| Average Basic Shares Outstanding | 11.47% | 7.12% | 2.53% | 5.07% | 7.25% |
| Average Diluted Shares Outstanding | 11.47% | 7.12% | 2.53% | 5.07% | 5.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |